Target | IL-12/IL-23 p40 |
---|
Application | FA, FC, IF |
---|
Clonality | Monoclonal |
---|
Conjugate | DyLight® 488 |
---|
Isotype | Human IgG1λ |
---|
Immunogen | This antibody was produced by phage display technology. |
---|
Species Reactivity | Human |
---|
Formulation | This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
---|
Research Area | Cancer, Immunology |
---|
Description/Background | Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects. |
---|
Storage Temperature | This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. |
---|
Protocols | FA, FC, IF |
---|
Clone Number | ABT-874 |
---|
Concentration | 0.2 mg/ml |
---|
Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |
---|